Table 1.
Baseline Characteristics According to mAb Treatment Status for Primary Matched Cohort
| Characteristic | mAb Treated (n = 2,675) | mAb Untreated (n = 6,677) |
|---|---|---|
| Age, ya | ||
| 18-54 | 1,018 (38.1) | 3,025 (45.3) |
| 55-64 | 569 (21.3) | 1,635 (24.5) |
| ≥ 65 | 1,088 (40.7) | 2,017 (30.2) |
| Femalea | 1,453 (54.3) | 3,705 (55.5) |
| Race/ethnicitya | ||
| Non-Hispanic White | 2,215 (82.8) | 5,323 (79.7) |
| Hispanic | 264 (9.9) | 775 (11.6) |
| Non-Hispanic Black | 64 (2.4) | 189 (2.8) |
| Other | 132 (4.9) | 390 (5.8) |
| Insurance statusa | ||
| Private/commercial | 1,355 (50.7) | 3,840 (57.5) |
| Medicare | 1,052 (39.3) | 1,989 (29.8) |
| Medicaid | 164 (6.1) | 543 (8.1) |
| None/uninsured | 44 (1.6) | 118 (1.8) |
| Other/unknown | 60 (2.2) | 187 (2.8) |
| BMI, kg/m2a | ||
| < 18.5 | 23 (0.9) | 60 (0.9) |
| 18.5-24.9 | 362 (13.5) | 875 (13.1) |
| 25.0-29.9 | 571 (21.3) | 1,374 (20.6) |
| ≥ 30.0 | 770 (28.8) | 2,013 (30.1) |
| Missing | 949 (35.5) | 2,355 (35.3) |
| Immunocompromiseda | 809 (30.2) | 1,677 (25.1) |
| No. of other comorbid conditionsa | ||
| 0 | 708 (26.5) | 1,837 (27.5) |
| 1 | 681 (25.5) | 1,967 (29.5) |
| ≥ 2 | 1,286 (48.1) | 2,873 (43.0) |
| Diabetes | 561 (21.0) | 1,173 (17.6) |
| Cardiovascular disease | 557 (20.8) | 1,290 (19.3) |
| Pulmonary disease | 891 (33.3) | 2,109 (31.6) |
| Renal disease | 344 (12.9) | 607 (9.1) |
| Hypertension | 1,293 (48.3) | 2,881 (43.1) |
| Obesity | 808 (30.2) | 2,073 (31.0) |
| Vaccination status | ||
| Not known to be vaccinated | 1,620 (60.6) | 4,394 (65.8) |
| Partially vaccinated | 148 (5.5) | 485 (7.3) |
| Fully vaccinated | 907 (33.9) | 1,798 (26.9) |
| Pandemic phase | ||
| Pre-Alpha: November 2020-February 2021 | 388 (14.5) | 984 (14.7) |
| Alpha: March 2021-June 2021 | 615 (23.0) | 1,794 (26.9) |
| Delta: July 2021-September 2021 | 1,672 (62.5) | 3,899 (58.4) |
| Type of monoclonal antibody | ||
| Bamlanivimab | 413 (15.4) | … |
| Bamlanivimab + etesevimab | 87 (3.3) | … |
| Casirivimab + imdevimab | 2,157 (80.6) | … |
| Sotrovimab | 18 (0.7) | … |
Data are presented as No. (%).
a
Variables used in the propensity matching. mAb = monoclonal antibody.